Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Here's Why

Key Points

• Nanobiotix shares opened at $25.61, after previously closing at $20.97, and last traded at $26.07 with a volume of 114,115 shares.
• Analysts have given Nanobiotix a consensus rating of "Hold" with an average target price of $11.00, while recent reports show mixed ratings including a "buy" from HC Wainwright.
• An institutional investor, Millennium Management LLC, recently acquired 13,452 shares in Nanobiotix, representing about 38.81% of the stock's current ownership by institutional investors.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $20.97, but opened at $25.61. Nanobiotix shares last traded at $26.07, with a volume of 114,115 shares.

Analyst Ratings Changes

Several analysts recently issued reports on NBTX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nanobiotix in a report on Saturday, September 27th. Leerink Partners set a $14.00 price objective on shares of Nanobiotix in a report on Thursday, September 18th. Finally, HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix has a consensus rating of "Hold" and an average target price of $11.00.

Nanobiotix Stock Up 22.3%

The business's 50 day moving average price is $10.88 and its 200-day moving average price is $6.52.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Millennium Management LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 13,452 shares of the company's stock, valued at approximately $39,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.